GSK3B and Alzheimer disease: Excessive enhancement of GSK‐3β activity has been shown to impair neuronal dendritic development and synaptic plasticity (Llorens‐Martin et al. 2013; Zhu et al. 2007), with such impairments being commonly observed in AD pathology (Kwok et al. 2008; Simone et al. 2020).